135 related articles for article (PubMed ID: 37663150)
1. The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare
Cui J; Tabbara S; Chadha J
SAGE Open Med Case Rep; 2023; 11():2050313X231196663. PubMed ID: 37663150
[No Abstract] [Full Text] [Related]
2. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
[TBL] [Abstract][Full Text] [Related]
3. A Primary Lung and Breast Cancer Patient with Germline
Li D; Liu X; Cui S; Yang D; Zhu Y; Pan E; Yang P; Dai Z
Onco Targets Ther; 2023; 16():17-22. PubMed ID: 36698436
[TBL] [Abstract][Full Text] [Related]
4. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
[TBL] [Abstract][Full Text] [Related]
6. Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18-18 and EGFR amplification: A case report.
Wang P; Fabre E; Martin A; Chouahnia K; Benabadji A; Matton L; Duchemann B
Front Oncol; 2022; 12():918855. PubMed ID: 35957870
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.
Cekay M; Arndt PF; Dumitrascu R; Savai R; Braeuninger A; Gattenloehner S; Steiner D; Roller F; Tello K; Hattar K; Seeger W; Sibelius U; Grimminger F; Eul B
Front Oncol; 2023; 13():1182391. PubMed ID: 37655099
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
9. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
10. Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
Guo T; Zhu L; Li W; Lin R; Ding Y; Kang Q; Shao L; Li C; Pan X
Lung Cancer; 2021 Nov; 161():94-97. PubMed ID: 34555730
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
Yang WJ; Gao YB; Qiu T; Wang YG; He J
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
[No Abstract] [Full Text] [Related]
12. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study.
Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
Biol Pharm Bull; 2023; 46(6):788-795. PubMed ID: 37258143
[TBL] [Abstract][Full Text] [Related]
13. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
16. Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring
Jonsdottir G; Smith M; Wood S; Hejleh TA; Furqan M
Transl Lung Cancer Res; 2023 Apr; 12(4):927-932. PubMed ID: 37197637
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Janning M; Süptitz J; Albers-Leischner C; Delpy P; Tufman A; Velthaus-Rusik JL; Reck M; Jung A; Kauffmann-Guerrero D; Bonzheim I; Brändlein S; Hummel HD; Wiesweg M; Schildhaus HU; Stratmann JA; Sebastian M; Alt J; Buth J; Esposito I; Berger J; Tögel L; Saalfeld FC; Wermke M; Merkelbach-Bruse S; Hillmer AM; Klauschen F; Bokemeyer C; Buettner R; Wolf J; Loges S;
Ann Oncol; 2022 Jun; 33(6):602-615. PubMed ID: 35263633
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
Zhang L; Yang X; Ming Z; Shi J; Lv X; Li W; Yuan B; Chen Y; Liu B; Qin K; Liu J; Wei Q; Gu D; Chen R; Yuan M; Cui J; Ou SI; Yang S
Clin Lung Cancer; 2022 Jun; 23(4):311-319. PubMed ID: 35045945
[TBL] [Abstract][Full Text] [Related]
19. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
Improta G; Zupa A; Natalicchio MI; Sisinni L; Marinaccio A; Bozza G; Vita G; Aieta M; Landriscina M
Med Oncol; 2018 Jan; 35(3):28. PubMed ID: 29387949
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report.
Louvet A; Honoré N; Dekairelle AF; Van Marcke C; Goeminne JC
Front Oncol; 2023; 13():1143775. PubMed ID: 37465107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
